Results 181 to 190 of about 5,314 (201)

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

Journal of Hepatology, 2019
Mar Riveiro-Barciela, Sabela Lens, Alba Cachero   +2 more
exaly  

Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir

Reactions Weekly
openaire   +1 more source

Ribavirin/sofosbuvir/velpatasvir

Reactions Weekly, 2023
openaire   +1 more source

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Clinical Infectious Diseases, 2017
Shyamasundaran Kottilil, Mark S Sulkowski, Susanna Naggie   +2 more
exaly  

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Clinical Infectious Diseases, 2016
Jason Grebely, Gregory J Dore, Graham R Foster   +2 more
exaly  

Sofosbuvir/velpatasvir

Reactions Weekly, 2020
openaire   +1 more source

Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis

Clinical Gastroenterology and Hepatology, 2017
Zobair M Younossi, Maria Stepanova, Jordan Feld   +2 more
exaly  

Sofosbuvir/Velpatasvir

Annals of Pharmacotherapy, 2017
Elias B Chahine
exaly  

Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial

The Lancet Gastroenterology and Hepatology, 2016
Zobair M Younossi, Maria Stepanova, Michael R Charlton   +2 more
exaly  

Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C

Drugs, 2016
Sarah L Greig
exaly